EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Glutaredoxin 2 Protein (Grx2) as an Independent Prognostic Factor Associated with the Survival of Colon Adenocarcinoma Patients

Marlena Brzozowa-Zasada iD, Adam Piecuch, Karolina Bajdak-Rusinek iD, Karolina Gołąbek iD, Marek Michalski iD, Kamil Janelt, Natalia Matysiak

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25021060 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Marlena Brzozowa-Zasada und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Histology and Cell Pathology in Zabrze, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-055 Katowice, Poland. Hauptthemen laut MEDLINE: Adenocarcinoma, Colonic Neoplasms, Glutaredoxins. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Silesia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glutaredoxin 2 (Grx2; Glrx2) is a glutathione-dependent oxidoreductase located in mitochondria, which is central to the regulation of glutathione homeostasis and mitochondrial redox, and plays a crucial role in highly metabolic tissues. In response to mitochondrial redox signals and oxidative stress, Grx2 can catalyze the oxidation and S-glutathionylation of membrane-bound thiol proteins in mitochondria. Therefore, it can have a significant impact on cancer development. To investigate this further, we performed an immunohistochemical analysis of Grx2 protein expression in colon adenocarcinoma samples collected from patients with primary colon adenocarcinoma (stage I and II) and patients with metastasis to regional lymph nodes (stage III). The results of our study revealed a significant relationship between the immunohistochemical expression of Grx2 and tumor histological grade, depth of invasion, regional lymph node involvement, angioinvasion, staging, and PCNA immunohistochemical expression. It was found that 87% of patients with stage I had high levels of Grx2 expression. In contrast, only 33% of patients with stage II and 1% of patients with stage III had high levels of Grx2 expression. Moreover, the multivariate analysis revealed that the immunohistochemical expression of Grx2 protein apart from the grade of tumor differentiation was an independent prognostic factors for the survival of patients with colon adenocarcinoma. Studies analyzing Grx2 levels in patients’ blood confirmed that the highest levels of serum Grx2 protein was also found in stage I patients, which was reflected in the survival curves. A higher level of Grx2 in the serum has been associated with a more favorable outcome. These results were supported by in vitro analysis conducted on colorectal cancer cell lines that corresponded to stages I, II, and III of colorectal cancer, using qRT-PCR and Western Blot.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenocarcinomaColonic NeoplasmsGlutaredoxinsHumansGlutathioneGlutathione ReductaseMembrane ProteinsPrognosis

Stichwörter der Autor:innen

ELISAGrx2S-gluathionylationcolon adenocarcinomaglutaredoxinsglutathione (GSH)oxidative stressprognostic factorredox balance

Substanzen

GlutaredoxinsGlutathioneGlutathione ReductaseMembrane ProteinsGLRX2 protein, human

Autor:innen und Institutionen

  • Department of Histology and Cell Pathology in Zabrze, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-055 Katowice, Poland.
  • Department of Medical Genetics, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-055 Katowice, Poland.
  • Department of Medical and Molecular Biology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Jordana 19, 41-808 Zabrze, Poland.
  • Zabrze Silesian Nanomicroscopy Centre in Zabrze, Silesia LabMed-Research and Implementation Centre, Medical University of Silesia, 40-055 Katowice, Poland.

ORCID-Profile: Marlena Brzozowa-Zasada, Karolina Bajdak-Rusinek, Karolina Gołąbek, Marek Michalski

Förderung

  • Medical University of Silesia

Zitieren

APA

Brzozowa-Zasada, M., Piecuch, A., Bajdak-Rusinek, K., Gołąbek, K., Michalski, M., Janelt, K., & Matysiak, N. (2024). Glutaredoxin 2 Protein (Grx2) as an Independent Prognostic Factor Associated with the Survival of Colon Adenocarcinoma Patients. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25021060

Vancouver

Brzozowa-Zasada M, Piecuch A, Bajdak-Rusinek K, Gołąbek K, Michalski M, Janelt K, et al. Glutaredoxin 2 Protein (Grx2) as an Independent Prognostic Factor Associated with the Survival of Colon Adenocarcinoma Patients. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25021060

BibTeX
@article{BrzozowaZasada2024,
  author = {Brzozowa-Zasada, Marlena and Piecuch, Adam and Bajdak-Rusinek, Karolina and Gołąbek, Karolina and Michalski, Marek and Janelt, Kamil and Matysiak, Natalia},
  title = {Glutaredoxin 2 Protein (Grx2) as an Independent Prognostic Factor Associated with the Survival of Colon Adenocarcinoma Patients},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25021060}
}
Kostenlos starten →